Intuitive Surgical, Inc.
HealthcareNASDAQ:ISRG · NASDAQ Global Select
-$4.81 today
Vol 0.84M · Avg 2.56M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$10.6B of revenue converted into $3.0B of net income for the selected period. Gross margin is 66.3% and net margin is 28.1%, showing how much revenue survives after costs and taxes. EPS is $8.25, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1B +20.5% | $8.4B +17.2% | $7.1B +14.5% | $6.2B +9.0% | $5.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.4B +25.9% | $2.7B +13.5% | $2.4B +18.2% | $2.0B +15.7% | $1.8B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.6B +17.9% | $5.6B +19.1% | $4.7B +12.7% | $4.2B +6.0% | $4.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 66.0% -1.5pp | 67.5% +1.1pp | 66.4% -1.0pp | 67.4% -1.9pp | 69.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.3B +14.5% | $1.1B +14.7% | $998.8M +13.6% | $879.0M +31.0% | $671.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.4B +11.4% | $2.1B +9.0% | $2.0B +12.9% | $1.7B +18.6% | $1.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.7B +12.5% | $3.3B +10.9% | $3.0B +13.1% | $2.6B +22.5% | $2.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $677.1M +46.6% | $462.0M +14.9% | $402.2M +10.0% | $365.8M +15.4% | $317.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $4.0B +27.2% | $3.1B +32.8% | $2.4B +19.7% | $2.0B -10.6% | $2.2B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 39.6% +2.1pp | 37.5% +4.4pp | 33.1% +1.4pp | 31.7% -7.0pp | 38.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $2.9B +25.4% | $2.3B +32.9% | $1.8B +12.0% | $1.6B -13.4% | $1.8B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 29.3% +1.1pp | 28.1% +3.3pp | 24.8% -0.5pp | 25.3% -6.5pp | 31.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $365.9M +12.6% | $324.9M +69.1% | $192.1M +546.8% | $29.7M -57.1% | $69.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $365.9M +12.6% | $324.9M +69.1% | $192.1M +546.8% | $29.7M -57.1% | $69.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $3.3B +23.8% | $2.7B +36.5% | $2.0B +21.9% | $1.6B -15.0% | $1.9B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 32.9% +0.9pp | 32.0% +4.5pp | 27.5% +1.7pp | 25.8% -7.3pp | 33.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $434.8M +29.3% | $336.3M +137.5% | $141.6M -46.0% | $262.4M +61.8% | $162.2M | $1.3B | -$1.6B | $745.2M |
| Net Income | $2.9B +23.0% | $2.3B +29.2% | $1.8B +36.0% | $1.3B -22.4% | $1.7B | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.4% +0.6pp | 27.8% +2.6pp | 25.2% +4.0pp | 21.3% -8.6pp | 29.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $8 +22.3% | $7 +27.7% | $5 +37.6% | $4 -22.3% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $8 +22.6% | $6 +27.6% | $5 +37.8% | $4 -21.7% | $5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $356.9M +0.5% | $355.2M +1.1% | $351.2M -1.3% | $355.7M -0.1% | $356.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $362.7M +0.2% | $362.0M +1.3% | $357.4M -1.3% | $362.0M -1.0% | $365.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.92B
ResMed Inc.
NYSE:RMD
$28.10B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.26B
Hologic, Inc.
HOLX
$16.97B
The Cooper Companies, Inc.
NASDAQ:COO
$13.21B
Baxter International Inc.
NYSE:BAX
$10.68B
Repligen Corporation
NASDAQ:RGEN
$7.55B
Teleflex Incorporated
NYSE:TFX
$5.82B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
ICU Medical, Inc.
NASDAQ:ICUI
$3.59B
Embecta Corp.
EMBC
$185.20M
Stereotaxis, Inc.
STXS
$178.37M
NEXGEL, Inc.
NXGL
$5.34M
Bionano Genomics, Inc.
BNGO
$3.86M
Innovative Eyewear, Inc.
LUCY
$3.54M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ISRG generate?
Intuitive Surgical, Inc. (ISRG) reported $10.06B of revenue in fiscal 2025.
Is ISRG profitable?
Intuitive Surgical, Inc. (ISRG) reported $2.86B of net income, with a net margin of 28.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.